HPRA advises of risk of medication errors with olaparib
- PDF / 151,327 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 40 Downloads / 223 Views
1
HPRA advises of risk of medication errors with olaparib Ireland’s Health Products Regulatory Authority (HPRA) has approved a Dear Healthcare Professional Communication from AstraZeneca Pharmaceuticals on the risk of medication errors if olaparib [Lynparza] formulations are switched. AstraZeneca in agreement with the European Medicines Agency (EMA) and the HPRA are informing healthcare professionals that Lynparza tablets and capsules are not to be substituted on a milligram-to milligram basis due to differences in their bioavailability and dosing. In order to avoid medication errors, the formulation and dosage of Lynparza should be specified on each prescription, and pharmacists should ensure that the correct formulation and dose is dispensed. Patients should be instructed on the dose of tablets or capsules they should use, and if the formulation is to be switched they should be informed of the difference in doses. They are at risk of overdose and a greater risk of adverse events if Lynparza capsules are used instead of tablets; conversely, use of tablets instead of capsules may result in lack of efficacy. The recommended dosage of Lynparza 50mg capsules is 400mg (8 capsules) twice daily, while the recommended dosage of Lynparza 150mg tablets is 300mg (2 tablets) twice daily. Lynparza 100mg tablets are available for tablet dose reductions. The Summary of Product Characteristics (SMPCs), package leaflets and packaging for both formulations of Lynparza includes advice that the formulation are not to be substituted on a milligram-to milligram basis. HPRA. LYNPARZA (Olaparib) - Important Safety Information from AstraZeneca Pharmaceuticals (Ireland) DAC as approved by the HPRA Internet Document : 27 Nov 2020. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/lynparza-(olaparib)---important-safety-information-from-astrazenecapharmaceuticals-(ireland)-dac-as-approved-by-the-hpra&id=46720e26-9782-6eee-9b55-ff00008c97d0 803521017
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
